Table 6: summarizing similar retrospective studies involving OCCC in the last 5 years

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Authors** | **Year** **Of****publication** | **Study design** | **Study Period** | **Number of patients** | **Endometriosis association** | **Early stage****I & II** | **Residual disease** | **Recurrence** |  **PFS** |  **OS** |
| Gallego A  | 2022 | retrospective | 1992- 2013 | 56 | 58.9% | 40.5% | 12.5% | - | - | ~60% (3-years) |
| Tranoulis A  | 2022 | retrospective | 2010 -2019 | 94 | 51% | ~50% stage I | 25% with endo10.9% with No endo |  | 39 months (in both groups ) | 55 months (no endo)71 months (with endo) |
| Kim SI | 2022 | retrospective | 1999-2018 | 2,962 | - | 74% | - | - | - | 74.9% (5 year) |
| Zhu C  | 2021 | retrospective | 2010-2022 | 86 | 18.6% | 68.6% | 10.46% | 26.53% | 3 years 78.95% (early) -22.2%(advanced) | 3 years89.47 %(early)-44.44% (advanced) |
| Zhou L  | 2021 | retrospective | 1998 - 2018 | 91 | 54% | 72.5% | 6.2% | 17.2% | 89.9% (5-year) | 88% (5-year) |
| Park JY | 2018 | retrospective | 1991-2012 | 155 | 50.3% | 76.7% | 14.19% | 32.9% | 5 years83% (endo)51% (no endo) | 5 years 84% (endo)54% (no endo) |
| Scarfone G | 2014 | retrospective | 1990-2012 | 73 | 36.9% | 56.1% | - | - | - | 5 years: 60% (no endo)-73% (endo) |